May 1, 2023 03:28 PM EDT
R&D
Pharma
Cell/Gene Tx

Bris­tol My­er­s' CAR-T Breyanzi hits end­points in two lym­phoma stud­ies

Paul Schloesser

Associate Editor

Bris­tol My­ers Squibb is tout­ing promis­ing da­ta for its block­buster CAR-T Breyanzi in two lym­phoma clin­i­cal tri­als.

The com­pa­ny said Mon­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times